PolyPid to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced its participation in two investor conferences in November 2020. The company will present at the H.C. Wainwright 6th Annual Israel Conference on November 12 at 1:30 PM ET and at the Stifel 2020 Virtual Healthcare Conference on November 17 at 8:00 AM ET. Additionally, PolyPid will engage in one-on-one meetings during the AGP Virtual Healthcare Symposium on November 19. The company specializes in prolonging drug release using its proprietary PLEX technology, focusing on unmet medical needs, particularly with its lead product candidate, D-PLEX100, in Phase 3 trials.

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences in November. Details on the presentations can be found below. The company will also participate in one-on-one investor meetings at the AGP Virtual Healthcare Symposium 2020 on Thursday, November 19.

H.C. Wainwright 6^th Annual Israel Conference

Date:	Thursday, November 12, 2020
Time:	1:30 PM Eastern Time

Stifel 2020 Virtual Healthcare Conference

Date:	Tuesday, November 17, 2020
Time:	8:00 AM Eastern Time
Webcast:	https://wsw.com/webcast/stifel27/pypd/2115344

About PolyPid
PolyPid is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. PolyPid’s product candidates are designed to address diseases with high unmet medical needs by pairing PLEX with drugs to deliver them directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. PolyPid’s lead product candidate, D-PLEX₁₀₀, is in Phase 3 clinical trials for the prevention of SSIs in different type of surgeries, including abdominal and open-heart surgery. PolyPid’s technology and products are based on the inventions of Dr. Noam Emanuel, the Founder and the Chief Scientific Officer of the company.

For additional company information, visit www.polypid.com.

Forward-looking Statements
This press release “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to our objectives, plans, and strategies, the expected timing of trials, the research, development, and use of our platform technologies, technologies, products and product candidates, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement filed pursuant to Rule 424(b)(4), filed with the SEC on June 29, 2020. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

FAQ

What conferences is PolyPid Ltd. participating in November 2020?

PolyPid Ltd. will participate in the H.C. Wainwright 6th Annual Israel Conference on November 12 and the Stifel 2020 Virtual Healthcare Conference on November 17.

What is the timing for PolyPid's presentations at the upcoming conferences?

PolyPid's presentation at the H.C. Wainwright Conference is scheduled for November 12 at 1:30 PM ET and at the Stifel Conference on November 17 at 8:00 AM ET.

Will PolyPid have one-on-one meetings with investors?

Yes, PolyPid will engage in one-on-one investor meetings at the AGP Virtual Healthcare Symposium on November 19, 2020.

What is D-PLEX100 and its significance?

D-PLEX100 is PolyPid's lead product candidate, currently in Phase 3 clinical trials for the prevention of surgical site infections (SSIs) in various surgeries.

What technology does PolyPid use for its therapeutics?

PolyPid utilizes its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology to develop targeted, locally administered, and prolonged-release therapeutics.